Setting the scene on U.S. Physical Therapy

With no fresh headline event driving U.S. Physical Therapy (USPH) today, investors are left weighing a share price of $76.83 alongside recent return figures and the company’s latest reported revenue and net income.

The recent share price pullback, including a 1-day share price return of 1.35% decline and a 30-day share price return of 11.63% decline, sits alongside a 1-year total shareholder return of 2.84%. This suggests that near term momentum has cooled while longer term results remain mixed.

If this has you reassessing where you allocate capital, it could be a good moment to broaden your search and check out our list of 33 healthcare AI stocks for more ideas.

With a recent share price pullback, annual revenue of US$773.343m, net income of US$21.572m, and a sizable gap to the analyst price target, you have to ask: is U.S. Physical Therapy undervalued, or is the market already pricing in future growth?

Price-to-Earnings of 53.9x: Is it justified?

At $76.83, U.S. Physical Therapy trades on a P/E of 53.9x, which makes the stock look expensive compared to both its peers and the wider U.S. Healthcare industry.

The P/E ratio compares the current share price to the company’s earnings per share and is a quick way to see how much investors are paying for each dollar of earnings. For a business like U.S. Physical Therapy, which operates outpatient clinics and industrial injury prevention services, this shows how highly the market is valuing its current profit stream.

Here, the gap is wide. The stock’s 53.9x P/E sits well above the U.S. Healthcare industry average of 22.1x and also above the peer average of 15.6x. It also exceeds an estimated fair P/E of 26.9x, a level the market could move towards if expectations around earnings or growth change.

Result: Price-to-Earnings of 53.9x (OVERVALUED)

However, recent multi year total returns in negative territory and a P/E that already assumes strong earnings can quickly sour sentiment if revenue growth slows or margins compress.

Another view on value: the cash flow angle

That rich 53.9x P/E tells one story, but our DCF model paints a very different picture. On this view, U.S. Physical Therapy at $76.83 is trading 56.3% below an estimated fair value of $175.69. If earnings were to align more closely with those cash flow assumptions, it raises the question of whether the market is being too cautious.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out U.S. Physical Therapy for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Overall the picture here is mixed. If this has caught your attention, take a moment to review the numbers yourself and weigh up 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop here, you might miss stocks that better fit your style, so use the screener and line up options that actually match your priorities.

• Target value first and sort through 48 high quality undervalued stocks that combine stronger fundamentals with prices that may not fully reflect them.
• Prioritize resilience and filter for solid balance sheet and fundamentals stocks screener (42 results) so you are focusing on companies with sturdier financial footing.
• Spot potential future leaders early by reviewing our screener containing 26 high quality undiscovered gems before they sit firmly on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.